XTL Biopharmaceuticals Ltd.
XTLB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $14 | $6 | $7 | $15 |
| - Cash | $0 | $1 | $2 | $3 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $13 | $4 | $5 | $12 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | -$0 | -$0 |
| % Margin | 0.7% | – | – | – |
| EBITDA | -$1 | -$1 | -$1 | -$1 |
| % Margin | -206.2% | – | – | – |
| Net Income | -$1 | -$0 | -$1 | $0 |
| % Margin | -227.7% | – | – | – |
| EPS Diluted | -0.15 | 0 | -0.25 | 0.07 |
| % Growth | – | 100% | -457.1% | – |
| Operating Cash Flow | -$2 | -$1 | -$1 | -$1 |
| Capital Expenditures | -$0 | $0 | $0 | $0 |
| Free Cash Flow | -$2 | -$1 | -$1 | -$1 |